The short answer
A generic drug demonstrates bioequivalence. The same active ingredient delivered at the same rate and extent. A biosimilar must demonstrate no clinically meaningful difference from its reference, usually requiring comparative clinical studies. Peptides of 40 residues or fewer take the first route.
Key facts
- Generic route
- ANDA (bioequivalence)
- Biosimilar route
- Comparative demonstration of similarity
- Deciding factor
- The 40-amino-acid threshold
- Semaglutide
- 31 residues (generic route)
- Consequence
- Faster entry, steeper price falls
- Cross-route sameness
- Synthetic may reference rDNA-origin
What bioequivalence actually requires
Showing that the proposed product delivers the same active ingredient into the body at the same rate and to the same extent as the reference. It is a pharmacokinetic demonstration, generally achievable without new efficacy trials, because the active ingredient is identical and identity can be established analytically.
Why biosimilars cannot do that
A large protein made in living cells is not identical between manufacturers. Glycosylation patterns and higher-order structure depend on the cell line and process, so no two products are the same molecule in the way two batches of a synthesised peptide are. Similarity therefore has to be demonstrated rather than asserted, which usually means comparative clinical work.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why a peptide escapes that
Because at 40 residues or fewer it can be synthesised chemically and characterised completely, sequence, mass, purity, impurity profile, all measurable. Where two products can be shown to be the same molecule by analysis, the reason for demanding comparative clinical evidence falls away.
The cross-route provision
The FDA accepts that an applicant may demonstrate a proposed synthetic peptide is the same as the active ingredient in a previously approved peptide of recombinant DNA origin. So a generic made by chemical synthesis can reference an innovator made in cells. Sameness attaches to the molecule, not to the process, which is a substantive regulatory position rather than a technicality.
What that means commercially
Entry measured in months rather than years, and by many manufacturers at once rather than a few. That is the mechanism behind the reported price falls of 70 to 90 per cent in India within weeks of expiry. Biosimilar markets do not behave that way, because the barrier to entry is far higher.
Where the line sits in this catalogue
Semaglutide at 31 residues, tirzepatide and retatrutide at 39, all on the drug side. IGF-1 LR3 at 83 residues would be handled as a biologic, which is consistent with its recombinant production and with the impurity profile discussed elsewhere on this site. None of this applies to research material, which holds no authorisation and no classification.
Quick reference
| Generic drug | Biosimilar | |
|---|---|---|
| Must show | Bioequivalence | No clinically meaningful difference |
| Clinical studies | Usually not required | Usually required |
| Applies to | ≤40 residues | >40 residues |
| Typical entry | Months, many entrants | Years, few entrants |
Frequently asked questions
What is the difference between a generic and a biosimilar?
A generic shows bioequivalence. The same active ingredient delivered the same way. A biosimilar shows no clinically meaningful difference, usually requiring comparative clinical studies.
Why can peptides use the generic route?
At 40 residues or fewer they can be synthesised and characterised completely, so sameness can be established analytically.
Can a synthetic generic reference a recombinant product?
Yes. The FDA accepts sameness demonstrated across manufacturing routes, because it attaches to the molecule rather than the process.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- FDAFDA: Drug Approval Searchaccessdata.fda.gov
- PubMedJaradat DMM, Thirteen decades of peptide synthesis. Amino Acids 2018 (PMID 29185032)pubmed.ncbi.nlm.nih.gov
- PubMedLi T et al., Production and characterization of highly purified recombinant thymosin beta 4. Protein Expr Purif 2013 (PMID 23711379)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Comparing an Operation With an InjectionA 2026 network meta-analysis compared metabolic and bariatric surgery against GLP-1 receptor agonists. Why the comparison is harder than it looks.
- Does Amylin Need a GLP-1 Partner?CagriSema pairs amylin with semaglutide and missed non-inferiority. A 2026 review surveys long-acting amylin peptides being developed on their own.
- The Trial Where Glucose-Dependence Shows Up in Numbers2,002 randomised, 52 weeks. Hypoglycaemia 6-9% with tirzepatide against 19% with glargine - and 1-3% versus 16% without a sulfonylurea.
- TRIUMPH-4: The First Retatrutide Phase 3 to Read OutTRIUMPH-4 randomised 445 adults with obesity and knee osteoarthritis. Co-primary endpoints, two estimands, and a pain result that did not track the dose.
- VESPER: What Is Actually Registered for BerobenatideSix VESPER trials, from a 239-person Phase 2b to a 3,578-person Phase 3. Registry records, enrolment, completion dates, and which acronyms are registered.